Circadian Integration of Glutamatergic Signals by Little SAAS in Novel Suprachiasmatic Circuits by Atkins, Norman et al.
Circadian Integration of Glutamatergic Signals by Little
SAAS in Novel Suprachiasmatic Circuits
Norman Atkins Jr.
1, Jennifer W. Mitchell
2, Elena V. Romanova
3, Daniel J. Morgan
4, Tara P. Cominski
4,
Jennifer L. Ecker
5, John E. Pintar
4, Jonathan V. Sweedler
1,3,6, Martha U. Gillette
1,2,3*
1Neuroscience Program, University of Illinois, Urbana, Illinois, United States of America, 2Department of Cell and Developmental Biology, University of Illinois, Urbana,
Illinois, United States of America, 3Beckman Institute for Advanced Science and Technology, University of Illinois, Urbana, Illinois, United States of America, 4Department
of Cell Biology and Neuroscience, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America, 5Department of Biology, The Johns
Hopkins University, Baltimore, Maryland, United States of America, 6Department of Chemistry, University of Illinois, Urbana, Illinois, United States of America
Abstract
Background: Neuropeptides are critical integrative elements within the central circadian clock in the suprachiasmatic
nucleus (SCN), where they mediate both cell-to-cell synchronization and phase adjustments that cause light entrainment.
Forward peptidomics identified little SAAS, derived from the proSAAS prohormone, among novel SCN peptides, but its role
in the SCN is poorly understood.
Methodology/Principal Findings: Little SAAS localization and co-expression with established SCN neuropeptides were
evaluated by immunohistochemistry using highly specific antisera and stereological analysis. Functional context was assessed
relative to c-FOS induction in light-stimulated animals and on neuronal circadian rhythms in glutamate-stimulated brain slices.
We found that little SAAS-expressing neurons comprise the third most abundant neuropeptidergic class (16.4%) with unusual
functional circuit contexts. Little SAAS is localized within the densely retinorecipient central SCN of both rat and mouse, but
not the retinohypothalamic tract (RHT). Some little SAAS colocalizes with vasoactive intestinal polypeptide (VIP) or gastrin-
releasing peptide (GRP), known mediators of light signals, but not arginine vasopressin (AVP). Nearly 50% of little SAAS
neurons express c-FOS in response to light exposure in early night. Blockade of signals that relay light information, via NMDA
receptors or VIP- and GRP-cognate receptors, has no effect on phase delays of circadian rhythms induced by little SAAS.
Conclusions/Significance: Little SAAS relays signals downstream of light/glutamatergic signaling from eye to SCN, and
independent of VIP and GRP action. These findings suggest that little SAAS forms a third SCN neuropeptidergic system,
processing light information and activating phase-shifts within novel circuits of the central circadian clock.
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Introduction
The hypothalamic suprachiasmatic nucleus (SCN) orchestrates
daily rhythms in brain and body functions and aligns them with
environmental day and night, processes fundamental to health and
longevity [1]. Functions coordinated by this master circadian clock
are diverse: behavioral rhythms of activity and rest, peak
performance in memory acquisition, release of pituitary hormones
into the portal system, oscillations in autonomic functions, time of
stem cell migration from the bone marrow into the blood stream,
and even disease vulnerabilities. Circadian timekeeping is a cellular
phenomenon, so the SCN must integrate its component cellular
clocks into a tissue-level clock and transmit coordinate time-of-day
information [2]. Because we live in an ever-changing world, the
SCN also must integrate ambient timing cues and, if necessary,
adjust its time-base to re-align brain and body processes. These
requirements impose exceptional modulatory demands at the input,
intra-SCN and output levels on the neurons and circuits that
comprise the master clock. Thus, neuropeptides are predicted to
participate in SCN functions to an unusual degree [3].
The internal structure of the SCN is complex [4]. Phenotypes
and functional roles of the ,10,000 SCN cells are incompletely
understood, although evidence indicates they are related to
neuropeptide expression [5]. Generalizations distilled from
localization patterns of peptides first described have been applied
to conceptually organize the SCN into a dichotomous structure.
Nevertheless, assessments based on differential and dynamic
peptide localizations, distribution and density of afferent projec-
tions, three-dimensional topography and rhythmic expressions of
clock genes and neuronal activities indicate that the SCN may be
significantly more complex [3,6,7,8,9,10,11,12]. The general
patterning of these features is conserved across mammalian
species, suggesting that such complexity is fundamental to SCN
functional organization [6,13,14,15,16].
Whereas only VIP and GRP have established roles in
synchronizing cellular oscillators and integrating/relaying light
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of the SCN peptidome report that peptide expression and release
are much more extensive and diverse than recognized previously
[3,7]. The SCN was found to express 102 neuropeptides identified
positively by mass spectrometry, but the functions of most are
unknown [11,15,17]. Why does the SCN express and release such
an abundance of neuropeptides? Elucidating the spatiotemporal
and functional contexts of newly identified peptides has emerged
as the challenge to fully understanding SCN physiology.
Little SAAS emerged through our high-throughput peptidomics
studies as a potentially prominent SCN neuropeptide. Derived
from the proSAAS prohormone (pcsk1n; UniProt Assession #
Q9QXU9) [18], which has been proposed to function as a
prohormone-processing enzyme, little SAAS was among the more
abundant neuropeptides detected in SCN releasate [3,7]. Its levels
change in the supraoptic nucleus in response to dehydration, but
function is not established [19]. An initial peptidomics study
reported that little SAAS is secreted spontaneously with circadian
rhythmicity from an SCN brain slice, where stimulating optic
nerve (ON) evokes little SAAS release and exogenous little SAAS
can alter endogenous rhythms of neuronal single unit activity
(SUA) [7]. Nevertheless, these observations do not establish little
SAAS as an endogenous SCN neuropeptide or a contributor to
circadian function in this complex tissue. The aim of our study is
to evaluate little SAAS localization, functional context and
integrative physiology with respect to known mediators of cell-
to-cell signaling in the SCN in order to better understand the
relative importance of this new SCN peptide discovered by
cutting-edge analytical chemistry.
Methods
Ethics statement
All experimental procedures were conducted at the University
of Illinois at Urbana-Champaign under protocols approved in
advance by the Institutional Animal Care and Use Committee
(IACUC) under Animal Welfare Assurance number A3118-01. All
care and experiments were conducted in full compliance with
principals and procedures outlines in the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Animals and circadian time
Seven-tothirteen-weekoldLongEvans/BluGillratswereusedin
this study. This inbred strain has been analyzed via dense genomic
scan (10 cM inter-marker interval), which confirmed only one allele
at eachlocus examined [20]. Animals were housed in 12:12 h light/
dark conditions with constant temperature and humidity, food and
wateradlibitum.Circadiantime (CT)designatesintrinsictime-of-day
regulated by the near-24-h endogenous oscillation of the SCN. In
the SCN brain slice, CT is an indicator of subjective day and night
for determining circadian time-points for exogenous treatments and
of endogenous clock state [21].
All mice used had a C57BL6 genetic background, including
controls, animals heterozygous for melanopsin-Cre (Opn4-Cre) and
Z/EG [22], and proSAAS +/y and 2/y. The ProSAAS null was
created by excision of proprotein convertase subtilisin/kexin type
1 inhibitor (pcsk1n) exon 1 and homologous recombination [23].
ProSAAS mouse brain tissue was prepared at the University of
Medicine and Dentistry of New Jersey and shipped to the
University of Illinois at Urbana-Champaign for processing.
Preparation of brain slices
Experiments utilized 500-mm coronal brain slices containing the
mid-SCN, prepared during daytime $2 h before the onset of the
dark phase, as preparation at night can alter clock phase [24,25].
Hypothalamic tissue was isolated from the brain, and coronal
slices were cut at 500 mm by mechanical chopper. Slices
containing the SCN were maintained in a brain slice chamber,
kept at constant temperature and gas conditions, perifused with
glucose-/bicarbonate-/gentamicin-supplemented Earle’s balanced
salt solution (EBSS, Hyclone) at 37uC and saturated with 95%
O2:5% CO2.
Brain slice treatments
Treatment of coronal SCN brain slices was performed with
perifusion pump stopped and EBSS level lowered slightly to
expose the tissue surface. Little SAAS, vasoactive intestinal
polypeptide (VIP), gastrin-releasing peptide (GRP), and [4Cl-D-
Phe
6, Leu
17] VIP were purchased from Phoenix Pharmaceuticals.
PD176252 was purchased from Tocris Bioscience. Peptides,
including little SAAS (various concentrations) and/or VIP/GRP
cocktail (100 nM each), were applied via 1-mL drop directly onto
each bilateral SCN visible at the brain slice surface. After 5 min,
the surface was rinsed with EBSS, and perifusion was resumed.
Antagonists, including little SAAS antiserum #2768 (undiluted) or
[4Cl-D-Phe
6, Leu
17] VIP/PD176252 antagonist cocktail (50 mM
each in 0.05% DMSO), were applied like agonists, 10 min prior to
EBSS rinse (control) or subsequent peptide treatment. Effective
concentrations for mL treatments are estimated to be diluted 10–
1006during diffusion into the tissue.
Recording of single unit activity (SUA)
Extracellular recording of spontaneous SUA of SCN neurons
has been described previously [26]. Briefly, the firing rate of an
individual neuron is recorded and its mean SUA determined over
4 min; the electrode is repositioned and the process repeated.
Two-hour mean SUAs are plotted versus circadian time (CT).
Running averages are based on 2-h epochs offset by 15-min
intervals. Calculation of circadian phase is based upon CT of peak
SUA.
Intracerebroventricular (i.c.v.) cannula implantation and
colchicine injections
Because colchicine has been reported to improve the ability to
visualize and count GRP-positive perikarya, which are obscured
by a dense fiber plexus [9], we injected colchicine i.c.v. in rats when
distributions of VIP, GRP and little SAAS would be compared
directly (not Fig. 1; Fig. 2 and Table 1, only). Male rats (250–
300 g) were administered buprenorphine (0.03 mg/kg; Reckitt
Benckiser Healthcare) pre-operatively 1 h prior to i.p. injection of
ketamine/medetomidine (75 mg/kg and 0.5 mg/kg, Fort Dodge
Animal Health and Pfizer Animal Health, respectively). A guide
cannula was implanted at stereotaxic coordinates targeting the
lateral ventricle (from bregma: A–P 20.9mm, M–L 21.40 mm,
D–V 23.5 mm). Animals were revived with atipamezole (1 mg/
kg; Pfizer Animal Health) and allowed to recover for at least 10
days under careful observation. Colchicine (5 mLo f1 0mg/mLi n
0.9% saline; SigmaAldrich) was injected i.c.v. into anesthetized,
cannulated rats over the course of 5 min. At 36 h post-treatment,
animals were deeply anesthetized and brains were prepared for
analysis.
Immunohistochemistry
At 4 h post-lights on, subjects were anesthetized with Euthasol
(100 mg/kg, Virbac) and perfused intracardially with 0.9% NaCl
followed by 300 ml of 4% paraformaldehyde in 0.1 M PBS.
Brains were removed, placed overnight in 4% paraformaldehyde,
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thick) were prepared using a VibratomeH (Leica Microsystems)
and rinsed 3610 min in PBS.
Immunohistochemical examination of little SAAS was conduct-
ed using rabbit anti-little SAAS antisera (#2766 or #2768) [27].
For little SAAS immunohistochemistry, sections from untreated
rats were incubated with rabbit anti-little SAAS antiserum, 1:5000
for 48 h at 4uC, and Alexa-FluorH 568 goat anti-rabbit IgG
(Molecular Probes), 1:1000 for 2 h at room temperature (RT).
Normal goat serum (Vector Labs) was used for blocking non-
specific staining (5%) and during antibody incubation (2%). For c-
FOS/little SAAS immunohistochemistry, sections collected from
brains of rats following exposure to light (400 lux, CT 14 for 1 h)
were incubated at 4uC in (1) normal bovine serum (5% for 2 h,
Jackson Immunoresearch), (2) goat anti-c-FOS (1:200 for 24 h,
Santa Cruz Biotechnology); (3) Biotin-SP-conjugated bovine anti-
goat IgG (1:400 for 1 h, Jackson Immunoresearch), and (4)
Fluorescein, DTAF-conjugated streptavidin (6 mg/ml for 1 h,
Jackson Immunoresearch). Following these steps, the tissue was
processed according to the little SAAS immunihistochemistry
protocol described above. PBS (3610 min) washes at RT were
performed between all steps, and PBS with 0.3% Triton X-100
(PBS-T) was used for all serum and antibody dilutions.
Immunohistochemistry involving GRP and/or VIP was per-
formed on colchicine-treated rat brain tissues. For GRP/little
SAAS double immunohistochemistry, sections first were blocked
for 2 h at RT in normal donkey serum/PBS-T (5%, Vector Labs).
Next, sections were incubated sequentially as follows: (1) goat anti-
GRP polyclonal antibody (1:50 for 48 h at 4uC; Santa Cruz
Biotechnology), (2) 3610 min in PBS; (3) Alexa-FluorH 488
donkey anti-goat IgG (1:1000 for 2 h at RT, Molecular Probes),
(4) 6610 min PBS; (5) normal goat serum/PBS-T (5%, Vector
Labs), (6) rabbit anti-little SAAS antiserum #2766 (1:5000 for
48 h at 4uC) [27], and (7) Alexa-FluorH 568 goat anti-rabbit IgG
(1:1000 for 2 h at RT, Molecular Probes). VIP/little SAAS double
immunohistochemistry included sequential incubations with (1)
normal goat serum/PBS-T (5%, 2 h at RT); (2) guinea pig anti-
VIP polyclonal antibody (1:8000 for 48 h at 4uC, Peninsula
Laboratories), (3) 3610 min in PBS; (4) Alexa-Fluor 488 goat anti-
guinea pig IgG (1:1000 for 2 h at RT, Molecular Probes), (5)
3610 min PBS; (6) rabbit anti-little SAAS antiserum (1:5000 for
48 h ); and (7) Alexa-FluorH 568 goat anti-rabbit IgG (1:1000 for
2 h at RT, Molecular Probes). Triple immunohistochemistry for
GRP, VIP, and little SAAS was performed first with GRP
immunohistochemistry, followed by 6610 min PBS, 5% normal
goat serum block for 2 h at RT, and steps (2) through (7), as
outlined for VIP/little SAAS double immunohistochemistry
above.
Mouse tissue for retinal immunohistochemistry was collected at
zeitgeber time 3 (ZT 3, 3 h following light onset). Melanopsin-
green fluorescent protein (GFP) transgenic mice were sacrificed by
cervical dislocation, and eyes were immediately excised and placed
into 4% paraformaldehyde overnight, followed by 24-h incubation
in 30% sucrose. Cryo-protected eye tissues were frozen in cryo-
molds in O.C.T. Compound (Tissue-Tek; Sakura Finetek).
Sections (35 mm) were cut by cryostat and dried for several hours.
Sections were post-fixed for 20 min in 4% paraformaldehyde,
blocked for 1 h in phosphate buffer containing 0.3% Triton X-
Figure 1. Little SAAS localizes to the central SCN of rat and mouse. Patterns of neuropeptide immunoreactivity in rat and mouse are
compared in mid-SCN coronal section. (A, D) Schematic of previously established neuropeptide expression [6,8,15] in sub-compartments (shading)
and somata (circles): AVP, orange; VIP, blue; GRP, green. (B,C,E,F) Photomicrographs of immunohistochemistry demonstrate that little SAAS
localization (green) in rat mid-SCN (B,C) is similar to that observed in mouse SCN (E,F). In both species, little SAAS-positive somata are primarily in the
central sub-compartment, although punctuate expression extends more broadly. Little SAAS (green) is shown double-labeled with arginine
vasopressin, AVP (B, red), vasoactive intestinal peptide, VIP (C, red), calbindin, CalB (E, red) or gastrin releasing peptide, GRP (F, red). Representative
higher magnification (inset, F) of little SAAS (green) and GRP (red) shows significant somatic co-localization (yellow). Each SCN is delineated by an
outer dashed line in the shape of an oval (rat) or teardrop (mouse). Localization of strong immunoreactivity for little SAAS is marked by an inner circle,
which corresponds to previous descriptions of the central SCN. Images are single optical sections (B,F, z=0.11mm; F inset, z=0.09 mm). OX, optic
chiasm; SCN, suprachiasmatic nucleus; 3V, third ventricle. Scale bar=50 mm.
doi:10.1371/journal.pone.0012612.g001
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heat-inactivated donkey serum (Millipore), and then stained for
two days in rabbit anti-little SAAS antiserum (1:4000), and chicken
anti-green fluorescent protein polyclonal antibody (1:1000 at 4uC,
Abcam). Incubation with secondary antibodies Alexa-FluorH 546
goat anti-rabbit IgG (1:600, Invitrogen) and FITC-conjugated
Figure 2. Little SAAS expression spans across VIP and GRP cytoarchitectonic regions of rat SCN. Confocal tile-scan images of coronal
tissue sections from rostal-to-caudal quadrants (vertical panels) reveal that little SAAS localizes to VIP- and GRP-expressing sub-compartments in all
quadrants. SCN are triple immunostained for VIP (white; A,F,K,P), GRP (green; B,G,L,Q), and little SAAS (red; C,H,M,R). Merge of images in the three
channels across each row (D,I,N,S) reveals co-localizations: VIP/little SAAS (pink), VIP/GRP (light green), and GRP/little SAAS (yellow). Enlargements of
these merged images appear in supplementary material (Figs. S2, S3, S4, S5). Schematic representations of each merge image (E, J, O, T) mark the
location of each stained soma in each optical slice: VIP (blue circles), GRP (green circles), little SAAS (red circles), VIP/little SAAS co-expressing (pink
diamonds), and GRP/little SAAS co-expressing (yellow diamonds). Gray arrowheads in B indicate non-specific staining of particulate introduced during
tissue mounting. Whereas VIP localizes primarily to the more ventromedial region, GRP occupies the more central SCN, as reported previously. Some
overlap with VIP exists along the medial edge of VIP localization, whereas laterally there is considerable overlap with GRP. Non-somatic
immunostaining marks peptide localized in cellular processes and puncta. Coronal sections (40 mm) are from colchicine-treated rat. Images in each
row are the same optical plane (z=0.11 mm). Approximate image coordinates provided in I, N, and S are relative to the rostral-most image (D,
designated as +0 mm). 3V, third ventricle; OX, optic chiasm. Scale bar (in S)=100 mm.
doi:10.1371/journal.pone.0012612.g002
Table 1. Quantitation of little SAAS-, VIP- and GRP-expressing neurons per rat SCN.
Number of Neurons per SCN Estimated Percentage per SCN
Little SAAS 16366247 16.36%
Vasoactive Intestinal Polypeptide (VIP) 22266373 22.26%
Gastrin-Releasing Peptide (GRP) 10626135 10.62%
Little SAAS/VIP 232665 2.32%
Little SAAS/GRP 842681 8.42%
Numbers of peptide-expressing neurons are estimated based on comparison of stereological counts to the total number of SCN neurons in colchicine-treated rats.
Estimated percentage values are based on an average number of 10,000 neurons per single rat SCN [4,8]. Little SAAS is co-expressed with VIP or GRP, respectively, in a
subset of neurons. However, co-expressing neurons do not account for the total number of little SAAS-positive neurons observed.
doi:10.1371/journal.pone.0012612.t001
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at RT in the dark. After PBS washes, tissue was cover-slipped in
Vectashield fluorescence mounting medium (Vector Laboratories).
For diaminobenzidine (DAB) staining, rat and ProSAAS +/y
(WT) and 2/y (null) mouse brains were sectioned coronally
(40 mm), rinsed 3610 min in PBS, incubated in 0.3% hydrogen
peroxide for 30 min, and rinsed again 3610 min in PBS at RT.
Non-specific staining was blocked using 5% normal goat serum in
PBS-T for 60 min at RT. Sections were incubated in rabbit anti-
little SAAS serum (1:32,000 for 48 h) and biotinylated goat anti-
rabbit IgG (1:200; Vector Laboratories) for 60 min, both at 4uC
with 3610 min PBS rinses following primary and secondary
antibody incubation. After incubation in the Vector Elite ABC
streptavidin horseradish peroxidase complex (1:28, 120 min at
4uC, Vector Laboratories) and 3610 min PBS washes, sections
were rinsed and developed using DAB, as described previously
[28]. After final immunohistochemistry steps, all fluorescence-
stained tissue sections were washed 3610 min in PBS, mounted on
SuperFrost Plus microscope slides (ThermoFisher Scientific),
dried, and coverslipped with ProLongH Gold antifade reagent
(Molecular Probes). Slides from DAB and immunohistochemistry
were dehydrated, defatted with Citrisol (ThermoFisher), and
coverslipped with Permount (ThermoFisher).
Imaging
Nissl sections were imaged using a Zeiss Axiolmager A1 light
microscope and the image acquisition functions in Stereo
Investigator software (MBF Bioscience, Williston, VT). DAB-
reacted sections were imaged using a Leica DM 6000B/CTR6000
light microscope under a 36objective lens by means of the Leica
Application Suite software. Fluorescence-immunolabeled images
were acquired using a Zeiss LSM-510 confocal microscope. For
image acquisition, amplifier gain, offset, respective excitation laser
power settings, and scan properties were optimized for each
objective lens to neurons displaying the lowest emission levels.
Some individual, single-optical slice images were captured as tiled
images across two-dimensional space and manually stitched
together using Adobe Photoshop CS2 (Adobe Systems, Inc.). No
other post-processing of acquired images was conducted. Individ-
ual peptide immunolocalizations are represented by red, green, or
white; co-localization is represented by pink or yellow. Microscope
software-rendered pseudocolor was confirmed as co-localization
using ‘Profile’ analysis of captured confocal images (Zeiss
Microsystems). Optical slice thickness for confocal images
captured with 206,4 0 6, and 1006 objective lens was 0.45 mm,
0.11, and 0.09 mm, respectively.
Light pulse for c-FOS induction
Rats were pair-housed in circadian activity monitoring system
(CAMS) prior to dark phase onset at ZT 12. At ZT 14, CAMS
lights were turned on (400-lux light for 60 min). Animals then
were removed from CAMS, euthanized, and perfused according
to procedures described above. Brain tissues were collected from
light-pulsed rats and compared to brain tissue samples obtained
from control animals in darkness at ZT 15.
SCN cell counting
Total numbers of little SAAS-, GRP-, and VIP-positive neurons
in a single, unilateral SCN were determined using a modified
version of a stereological method described previously [6]. Serial
coronal sections (40 mm) from the hypothalamus of colchicine-
treated rats were divided into three groups, referred to as ‘bins’,
each containing in a total of six SCN-inclusive sections at intervals
120 mm apart. Sections immunostained for either GRP/little
SAAS or VIP/little SAAS were subjected to stereological analysis
using a Zeiss AxioImager A1 microscope (Zeiss Microsystems) and
Stereo Investigator software (MBF Bioscience).
Total immunopositive cells were counted in six SCN-containing
sections from a single bin. Cells of only one SCN per section were
counted; counting was performed on the same side of each coronal
slice per group, as determined by orientation of the unilateral track
mark in the cerebral cortex left by the cannula used for injecting
colchicines for i.c.v. delivery. Total SCN volume was estimated by
measuring the area of a single SCN for each section analyzed and
multiplying the area by the thickness of the section. The sum of the
volume of all sections counted was multiplied by the total number
of groups to obtain the total SCN volume.
We observed that little SAAS immunoreactivity is generally
high in the peri-SCN hypothalamus. Little SAAS intensity
decreases markedly near the border of the SCN (Fig. S1). SCN
volume, determined by circumscribing the perimeter formed by
the marked decrease in little SAAS staining at the juxtaposition
with the surrounding extra-SCN hypothalamus, was not signifi-
cantly different from SCN volume calculated using Nissl staining.
Thus, this demarcation was used for subsequent determination of
SCN volume.
For each sample, the total cell count estimate was calculated as:
Total cell count estimate~
Cell count=Total sampling volume
Total SCN volume
To examine the relationship of little SAAS localization to light-
inducedc-FOS-likeimmunoreactivity,coronalbrainslicesfromlight
pulsed rats were double immunostained, as described above.
Immunostained samples were examined using cellcounting methods
modified from previous studies [29]. For each subject, bilateral SCN
from two mid-SCN coronal sections were analyzed using a Zeiss
AxioImager A1 microscope (Zeiss Microsystems) and Stereo
Investigator software (MBF Bioscience). Little SAAS, c-FOS, and
little SAAS/c-FOS double-positive neurons were marked and tallied
throughout the entire thickness of respective SCN. Only little SAAS-
positive neurons with discernable immunohistochemistry-sparse
nuclei were counted, and c-FOS-positive nuclei with discernable
nucleoli were counted. The total counts for the four respective SCN
from each animal were averaged, and a group average was
calculated.
Mass spectrometry analysis of peptides in rat optic nerve
Optic nerves, from retina to optic chiasm, were dissected from
rats immediately after decapitation and processed for peptide
extraction as described previously [30]. Briefly, isolated optic
nerve samples were placed individually in 20 mL of dihydrox-
ybenzoic acid solution (DHB: 20 mg/mL in water) for preserva-
tion and peptide extraction during 48-h incubation at 14uC.
Samples for MS were prepared by mixing 0.7 mL of DHB extract
1:1 with freshly prepared DHB matrix (50 mg/mL, 50% acetone)
directly on the MALDI sample plate and analyzed using a Bruker
ultraFlex II mass spectrometer (Bruker Daltonik) in positive
reflectron mode. Fragmentation spectra of selected peptides were
produced from the same samples in tandem MS mode (TOF/
TOF), and amino acid sequences were deduced using Bruker
Biotools software (Bruker Daltonik) with rapid de novo function.
Obtained sequence tags were searched against the MSDB and
NCBI protein databases via Mascot (Matrix Science, Boston, MA;
http://www.matrixscience.com) with 0.5 Da mass tolerance for
both parent and fragment ions. Matched peptides were manually
inspected for sequence fit.
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Analysis of data containing two groups was conducted using
Student’s t test. One-way ANOVA was used for comparison of
more than two groups with Bonferroni or Tukey-Kramer post-test.
Statistical significance was ascribed at p#0.05.
Results
Little SAAS localizes to the central SCN of rat and mouse
We evaluated brain tissues from rat and mouse by fluorescence
immunohistochemistry for known peptide markers while staining
for little SAAS immunoreactivity. Specificity of little SAAS
antisera was demonstrated by loss of immunoreactivity in tissues
of proSAAS-deficient transgenic mice (Fig. S1), as well as in rat
after pre-incubation of antisera with little SAAS peptide (data not
shown). Little SAAS immunoreactivity is evident in the SCN of
both rat and mouse (Fig. 1A–F). The shape of the SCN and
orientation of core and central sub-compartments differ slightly
between these species (Fig. 1A, D). Established geometries and
peptidergic markers of sub-compartments were compared to little
SAAS localization. At mid-SCN, in both rat and mouse, little
SAAS immunoreactivity appears mediolaterally in a circular
pattern (Fig. 1B, C, E, F). In both species, little SAAS is not
evident in the region marked by arginine vasopressin (AVP) and,
in mouse, also, calbindin. Little SAAS localization is less apparent
in regions marked by VIP than in the central area marked by GRP
in these mid-SCN sections.
To more thoroughly evaluate localization of little SAAS with
respect to VIP and GRP, tile scans of confocal images of triple-
labeled SCN tissue from rat were analyzed across rostro-to-caudal
quadrants (Fig. 2). The pattern of little SAAS localization shifts
from ventral in the rostral-most sections to central across the
remaining quadrants. The little SAAS pattern matches that of
GRP in the central SCN throughout middle and caudal planes.
Merged pseudo-color images show some co-localization of little
SAAS with VIP (pink) and GRP (yellow) (Fig. 2D, I, N, S, and Fig.
S2, S3, S4 and S5). Regions of VIP/little SAAS overlap conform
with the VIP sub-compartment that is extremely ventral in the
rostral SCN (Fig. 2D), then medial within the middle and caudal
SCN (Fig. 2H, L). This pattern of immunolocalization of VIP cells
in the ventromedial SCN, although more medial than observed in
some studies [6,8], corroborates a previous report of two VIP
neuronal subsets in the rat SCN [31]. GRP/little SAAS co-
localization is relatively sparse rostrally and then increases to high
density in the central SCN in the caudo-middle section, and more
dorso-lateral in the caudal quadrant. Punctate expression,
suggestive of pre-synaptic localization, also is observed. Overall,
little SAAS colocalizes within the major cytoarchitectonic sub-
compartments of VIP and GRP, appearing most intense in the
central area demarcated by GRP.
Volume and co-localization of little SAAS vs. VIP and GRP
cell populations
We undertook stereological evaluation of little SAAS-, VIP- and
GRP-expressing cells throughout the SCN. Little SAAS staining
surrounds the dorsal SCN border. This pattern of little SAAS
staining was evaluated as a marker delimiting the SCN. The Nissl-
stained SCN, the standard marker of total SCN tissue, was
compared to the extra-SCN region defined by dark staining for
little SAAS. Total SCN volume was calculated based on SCN area
in 40-mm serial coronal sections throughout the rostro-caudal axis.
These SCN volume estimates were normalized to volume
calculations based on Nissl staining, and show no significant
difference between the volume prescribed by little SAAS vs. Nissl
staining (p.0.95; data not shown).
Stereological analysis found an average of 1,6366247 little
SAAS neurons (n=6, based on 3 animals, two bins, counted per
animal each containing 6 SCN sections at 120- mm intervals) for
an estimated 16.4% of the ,10,000 neurons in a single SCN. By
comparison, VIP-expressing neurons (2,2266373; n=3 animals,
one bin counted) and GRP-expressing neurons (1,0626135; n=3,
one bin counted) account for 22.3% and 10.6% of the total
number of neurons in a single SCN, respectively (Table 1). Neither
GRP nor VIP neuron counts differ significantly compared to
values previously reported for the rat SCN (p.0.12 and p.0.28,
respectively, based on the Independent Groups T-test for Means)
[8]. This assessment finds little SAAS-positive neurons to be a
major peptidergic class, ranking after AVP and VIP and above
GRP. Little SAAS is co-expressed with 10.4% of the VIP neurons
(232665; n=3) and 79.2% of the GRP neurons (842681; n=3).
Little SAAS is colocalized with GRP in ,46more neurons than
with VIP, despite VIP-positive neurons being .26 more
abundant than GRP-expressing cells. It is noteworthy that the
total of little SAAS/VIP and little SAAS/GRP neurons accounts
for only ,66% of all little SAAS-positive neurons observed.
Light induces c-FOS in little SAAS neurons
Up-regulation of the immediate-early gene product, c-FOS,
following light exposure during the dark phase of the circadian
cycle is a hallmark of SCN activation: the intensity of c-FOS
induction is proportional to the amplitude of the resulting change
in phase of behavioral rhythms [32,33]. Under stimulus conditions
such as we used, which result in maximal delay, light-induced c-
FOS expression is limited to a subset of neurons in the central
SCN, implicating them in processing of the light signal [9,34,35].
In order to determine whether c-FOS is induced in little SAAS-
positive neurons in response to light, rats were exposed to a light
pulse at ZT 14 for 1 h and c-FOS localization was evaluated.
Compared to controls (Fig. 3A), c-FOS immunoreactivity (green)
overlaps with the region of dense little SAAS staining (red, Fig. 3B).
Neurons expressing c-FOS/little SAAS comprise 23.765.3% of
the total c-FOS-expressing neurons and 48.261.7% of little
SAAS-positive neurons (n=3; Fig. 3C). Thus, nearly 1/2 of little
SAAS-positive neurons in the rat SCN are targets of the light
signaling pathway, and ,1/4 of the c-FOS-positive population
express little SAAS neurons.
Little SAAS is not expressed in the RHT
Because little SAAS is released from the horizontal SCN brain
slice when the attached optic nerves innervating the SCN are
stimulated, little SAAS could be a neurochemical messenger of
retinohypothalamic tract (RHT) signaling from the eye. In order
to assess whether little SAAS peptide is expressed in the light input
pathway to the SCN, we examined little SAAS expression in retina
and optic nerve. Melanopsin-containing retinal ganglion cells
(RGCs) comprise 95% of the RGCs whose axons form the RHT
within the optic nerve [36]. They are intrinsically photoreceptive
elements of the circadian system and deliver light information
directly to the SCN. Double immunohistochemistry of retinal
tissue from the melanopsin-GFP transgenic mouse strongly
immunolabeled melanopsin-GFP RGCs (green; Fig. 4A), but no
little SAAS immunoreactivity above background was detected
(red; Fig. 4B). Overlaying red and green channels confirms that
melanopsin-GFP immunoreactivity does not colocalize little SAAS
(Fig. 4C).
To evaluate little SAAS peptide content of optic nerve tissue
from rat, we used matrix-assisted laser desorption/ionization-time
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spectra reveal the presence of a peak at m/z 1784.93, which
corresponds to the theoretical mass of the protonated ion for little
SAAS (m/z 1784.97) (Fig. 4D). However, de novo sequencing by
tandem MS performed on the 1784.9 peak identified it as
acetylated N-terminus fragment of myelin basic protein, MBPS
(ac)ASQKRPSQRHGSKY, theoretical m/z=1784.94 (Fig. 4E).
The peptide exhibited a characteristic loss of CH2CO from the
acetyl group as a result of metastable fragmentation when
analyzed in reflectron mode. Numerous other MBPs fragments
were identified as well, thereby further confirming the origin of the
1784.9 peak in the ON extract analyzed. Thus, little SAAS is not
present in either melanopsin-RGCs or optic nerve tissue in
detectable amounts, and neither would be a source of little SAAS
detected in releasate at the SCN upon optic nerve stimulation.
Little SAAS acts downstream of NMDA-receptor signaling
The primary mechanism by which the RHT communicates
phase delay is glutamate signaling via NMDA receptor (NMDAR)
activation, an event that is both necessary and sufficient to shift
SCN phase [24]. To evaluate whether little SAAS functions
downstream of the NMDAR, the competitive NMDAR antago-
nist, (2R)-amino-5-phosphonovaleric acid (APV; 1 mL drop/SCN,
100 mM), was applied to the SCN brain slice 10 min prior to
application of little SAAS (1 mL drop/SCN, 1 nM) at CT14. APV
alone does not alter clock timing (20.0460.52 h; n=3; Fig. 5B, I).
Further, APV does not alter the little SAAS-induced phase delay
(22.2560.60 h; n=4; Fig. 5C, I).
To assess whether little SAAS is required for intercellular
communication within the SCN during glutamatergic phase delay,
the SCN was pre-incubated (10 min) with a 1 mL drop of
undiluted little SAAS antiserum and then treated with glutamate
(1 mL drop, 10 mM), both applied directly to the SCN in the brain
slice. Little SAAS antiserum alone does not alter SCN phase
(Fig. 5G, I). When applied prior to glutamate at CT 14, little
SAAS antiserum blocks glutamate-induced phase delay
(0.9460.72 h; n=4; Fig. 5H, I) compared to glutamate alone
(22.5460.14 h; n=3; p#0.01, one-way ANOVA with Bonfer-
roni post-hoc test; Fig. 5F, I). Further, little SAAS antiserum does
not block phase delay caused by a cocktail of VIP and GRP
(22.3860.43 h; n=3; p#0.01, one-way ANOVA with Bonfer-
roni post-hoc test; Fig. 5I).
Little SAAS signaling is independent of VPAC2R/BB2R
signaling
VIP and GRP, acting via their respective G protein-coupled
receptors, VPAC2R and BB2R, respectively, mediate intra-SCN
communication driving synchronous phase shifting of the SCN
[11,17]. To evaluate whether VPAC2R and BB2R signaling is
downstream of little SAAS phase delay at CT14, a cocktail
containing selective antagonists for VPAC2R ([4Cl-D-Phe
6, Leu
17]
VIP, 50mM) [37,38,39] and BB2R (PD176252, 50mM) [40,41]
was used (Fig. 6). The antagonist cocktail (50 mM each in 1 mL/
SCN drop/10 min) does not affect clock phase (0.0460.29 h;
n=3). Whereas application of a VIP/GRP cocktail (100 mM each
in 1 mL) causes the anticipated delay in clock phase
(22.9660.52 h; n=3; p#0.01, one-way ANOVA with Tukey-
Kramer post-test), this effect is blocked fully by pre-incubation
with the VPAC2R/BB2R antagonist cocktail (0.1360.20 h; n=4).
Pre-treatment with this antagonist cocktail (1 mM in1 mL drop) has
no effect on the amplitude of phase delay caused by little SAAS
(21.9460.43 h; n=4; p#0.01, one-way ANOVA with Tukey-
Kramer post-hoc test).
Figure 3. Light-induced c-FOS colocalizes with little SAAS in
subset of neurons in the central SCN. (A–B) Confocal tile-scan images
of SCN-containing coronal tissue sections from a rat receiving no light
exposure vs. 400-lux light at CT 14 for 1 h. Light induction of c-FOS (green)
is within the region of little SAAS staining (red) in the ventrolateral core
SCN. High magnification optical section (z=0.09 mm) reveals c-FOS
(nuclear) and little SAAS (cytoplasmic) within the same cell. (C) Cell
counting from mid-SCN sections found 23.765.3% of c-FOS-positive
neurons also are little SAAS-positive, while 48.261.7% of little SAAS-
positive neurons are also c-FOS positive. Tissue section thickness=40 mm;
optical image depth=0.11 mm; 3V, third ventricle; OX, optic chiasm. Scale
bar, A–B (shown in B)=100 mm; scale bar, B inset=10 mm.
doi:10.1371/journal.pone.0012612.g003
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This study evaluates the localization and functional context of
little SAAS within neuropeptidergic circuits of the SCN. We find
that little SAAS is expressed in the central sub-compartment of rat
and mouse, but is not detected in either SCN-projecting
melanopsin RGCs of the retina or optic nerve tissue. Triple
immunohistochemistry for VIP, GRP and little SAAS reveals a
combination of single- and multi-peptide-expressing cellular
phenotypes that colocalize most densely within the central SCN.
Little SAAS is a major class of peptide-expressing neurons within
the SCN, more abundant than GRP. About 50% of little SAAS
neurons respond to light exposure in early nighttime with
induction of c-FOS. The partial response of little SAAS neurons
to light with c-FOS induction may indicate that the neurons not
responding participate in integrating distinct features of the
stimulus coming from the retina. Alternatively, part of the little
SAAS subpopulation may have an entirely different role from the
light-responders, such as integrating input from the thalamus or
raphe.
Exogenous little SAAS peptide applied to the SCN brain slice
during early subjective nighttime (CT 14) elicits phase delay of the
SCN rhythm of neuronal firing rate. Pharmacological blockade of
the NMDA receptor does not alter the ability of little SAAS to
cause phase delay, nor does inhibition of VPAC2/BB2 receptors.
This places little SAAS as a signaling element in an intra-SCN
circuit, downstream of NMDAR activation and distinct from VIP/
GRP signaling (Fig. 7).
This study defines the functional context of a new SCN peptide
discovered by forward peptidomics. It builds upon direct mass
spectrometric identification of a molecular species, but relies on
the specificity of antisera, which are indirect reagents. Thus,
demonstration of antisera specificity is critical. The little SAAS
antisera used in this study are highly specific; patterned
immunoreactivity in the wild-type mouse brain is similar to rat,
and is absent in the brain of the proSAAS null mouse.
Additionally, pre-absorption of little SAAS antibodies with little
SAAS peptide or application of only the secondary antibody does
not result in immunostaining of rat hypothalamic tissue. One of
the little SAAS antisera used in this study (#2766) previously has
been reported to strongly recognize its immunogenic peptide, little
SAAS (proSAAS-(42–59)), as well as big SAAS (proSAAS-(34–59)),
but not the KEP peptide (proSAAS-(34–40)) [27]. The same
antiserum also has demonstrated some affinity for synthetic full-
length proSAAS. Peptidomic studies of SON and SCN tissue
extracts identified a number of truncated forms of little SAAS
[3,42]; however, only little SAAS (proSAAS-(42–59)) has been
detected in releasates from the rat SCN under physiological
conditions [7], emphasizing that little SAAS (proSAAS-(42–59)) is
likely a physiological form of this peptide.
The discrete localization of little SAAS within the central SCN
predicts a role in processing afferent signals. This region receives
light information through direct projections from the eye through
the RHT. Axons of melanopsin RGCs that form the RHT
colocalize glutamate and PACAP in terminals that invest the SCN
[43,44,45]. Little SAAS action in the SCN does not originate from
direct retinal projections; this is indicated by absence of either little
SAAS immunoreactivity in the melanopsin RGCs of mouse or
bona fide little SAAS peptide determined by mass spectrometry of
the ON of rat. Rather, little SAAS may be entirely endogenous to
the SCN or some could be released from non-RHT afferents.
The central and ventromedial regions of the SCN also receive
indirect projections from the eye through the geniculohypotha-
lamic tract [6,10]. In addition, there is overlapping innervation
Figure 4. Little SAAS is not expressed in mouse melanopsin-positive retinal ganglion cells or rat optic nerve. (A–C) Confocal
micrographs of male melanopsin-GFP transgenic mouse retina. (A) GFP-immunoreactivity (green) is localized to melanopsin-expressing cell bodies of
the ganglion cell layer (GCL). (B) Little SAAS staining (red) is not observed above non-specific background levels in the same layer of retina. (C)
Overlay of both channels shows no co-expression of little SAAS and melanopsin-GFP. (D–E) Mass spectrometry analysis of peptides in rat optic nerve.
(D) Representative peptide profile of the optic nerve as detected by MALDI-TOF MS in extracts of individual nerve samples. Major peak at m/z 1784.9
corresponds to myelin basic protein (MBPs). Other truncated forms of MBPS verified by tandem MS are labeled. (E) Tandem mass spectrometry by
MALDI-TOF/TOF confirms identity of the 1784.9 peak as acetylated N-terminus fragment of MBPS. GCL, ganglion cell layer of the retina; INL, inner
nuclear layer of the retina; IPL, inner plexiform layer of the retina; ME, median eminence; ONL, outer nuclear layer of the retina; OPL, outer plexiform
layer of the retina; scale bar, C=100 mm.
doi:10.1371/journal.pone.0012612.g004
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photic pathways have been implicated in generating mid-day
phase advances and attenuating glutamatergic, light-stimulated
phase shifts during the nighttime [46,47,48,49]. Convergence of
multiple afferents on overlapping topographical targets provides
strong evidence that neurons there comprise local circuits through
Figure 5. Little SAAS acts downstream of NMDAR and parallel to VIP/GRP signaling during early night. (A, I) SCN in a coronal brain slice
displays characteristic mid-subjective daytime peak at CT 7 in spontaneous rhythm of neuronal firing rate. (B, I) The competitive NMDAR antagonist,
APV (100 mM), does not alter phase. (C, I) Application of little SAAS following pre-treatment with APV results in phase delay. (D, I) Application of little
SAAS alone causes a similar phase delay. (E, I) Firing rate rhythm in control SCN slice with peak at CT 7. (F, I) Application of glutamate (10 mM, 1mL
drop) at CT 14 causes phase delay. (G, I) Application of little SAAS antiserum (#2768,undiluted) does not significantly alter SCN phasing. (H, I) Little
SAAS antiserum blocks the phase delay induced by glutamate. (I) Mean data demonstrate that whereas the NMDAR antagonist, APV, does not block
little SAAS action, little SAAS antiserum blocks the phase delaying effect of glutamate, but does not affect not the phase delay stimulated by the GRP/
VIP cocktail. n$3 for all groups; **, p#0.001 vs. control, one-way ANOVA with Bonferroni post-hoc test.
doi:10.1371/journal.pone.0012612.g005
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environmental or organismal change.
VIP- and GRP-expressing neurons are integral components of
the SCN circuitry that synchronizes cellular clocks and generates
coherent light-induced resetting of clock phase
[50,51,52,53,54,55,56,57]. Both peptidergic populations extend
collateral processes locally, as well as to the dorsal AVP-containing
region [58]. Either singly or together as a cocktail, VIP and GRP
are effective activators of light-like resetting of behavioral rhythms
[59,60]. The action of VIP and GRP on phase shifting is conveyed
via the VPAC2 and BB2 receptors, respectively. Activation of
these receptors has been linked to propagating the induction of
Period genes within the SCN during the light response of mouse
and rat [52,61]. These findings suggest that VIP and GRP may
interact at the circuit level to achieve a wide range of responses.
Co-localization of little SAAS with subsets of VIP and GRP
neurons in the central sub-compartment suggests that little SAAS
also could participate in signal integration and relay within SCN
circuits (Fig. 7). This possibility is supported by the relatively large
percentage of SCN neurons containing little SAAS. Stereological
examination finds that little SAAS is the third most abundant
peptidergic class, after AVP and VIP, identified to date in the rat
SCN [4]. Whereas only ,10% of VIP neurons are little SAAS-
positive, nearly 80% of GRP neurons co-localize little SAAS.
Moreover, the total number of little SAAS-positive neurons is
higher than the number of little SAAS/VIP and little SAAS/GRP
co-expressing neurons. These data support the conjecture that
little SAAS marks a functionally important peptidergic subpopu-
lation that is not accounted for by previously defined SCN
neurons.
Our findings support a role for little SAAS in the signal
integration and relay circuitry that mediates the circadian light
response. c-FOS induction in central and core SCN neurons is an
established marker of light activation. In the mouse SCN, roughly
70% of the GRP-expressing neurons exhibit light responsive c-FOS
induction [9]. In our assessment, approximately 50% of little SAAS
neurons in rat express c-FOS following light pulse. Thus, despite
species differences, light-responsive little SAAS and GRP neurons
are similar numerically to the number of little SAAS/GRP co-
expressing neurons determined through our stereological analysis.
Nevertheless, the NMDA antagonist, AP-5, which effectively blocks
light-like phase shifts caused by glutamate or NMDA [62], fails to
block the phase-shifting effects of little SAAS. This is in contrast to
the finding that NMDA antagonists do block the phase shifting
effects of GRP [63]. This further distinguishes little SAAS from the
other SCN neuropeptides. It is noteworthy that little SAAS and
GRP have such a high co-localization and yet have apparently
differing relationships to NMDA-dependent signal transduction in
the SCN. Taken together, these data raise questions as to whether
little SAAS/GRP co-expressing neurons have a specific role in the
SCN response to light, a finding that warrants investigation.
The light responsiveness of little SAAS neurons, combined with
the insensitivity of the little-SAAS phase shift to blockade of VIP
and GRP receptors, tentatively places little SAAS in SCN circuitry
Figure 6. Effects of little SAAS on SCN phasing are independent of VPAC2/BB2 signaling. Microdrop application to the SCN at CT 14 of
little SAAS (1 or 100 nM) or VIP/GRP (100 nM each) induces significant phase delay compared with controls (p#0.01). Pre-incubation with a cocktail of
VPAC2 receptor antagonist [4Cl-D-Phe,Leu]VIP (50 mM)/BB2 receptor antagonist PD176252 (50 mM) does not alter SCN phasing (0.0460.29 h) vs.
controls. The antagonist cocktail does not alter the phase delay induced by little SAAS (21.9460.43) but fully blocks the phase shift induced by a VIP/
GRP (20.1360.20 h). n$3 for all groups; **, p#0.01 vs. control; $, p#0.01 vs. 100 nM VIP/GRP cocktail; #, p#0.05 vs. 100 nM VIP/GRP cocktail, one-
way ANOVA w/Tukey-Kramer post-hoc test.
doi:10.1371/journal.pone.0012612.g006
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VIP/GRP (Fig. 7). Previously, we determined that exogenous little
SAAS is capable of shifting the phase of the circadian clock in the
SCN brain slice during early night, similar to phase delays evoked
by VIP and GRP [7,53,54]. Little SAAS release from the SCN
slice is low during subjective nighttime [7], coinciding with high
Figure 7. Model of light signal processing in the rat SCN. (A) Schematic of general functional organization within the rat SCN (coronal section,
mid-SCN). SCN regions (ventral, dark blue; central, light blue; and dorsomedial, purple) denote functionally distinct regions that receive and integrate
different signals (central/ventral) and relay this information locally and to the dorsomedial SCN. These regions also extend efferents to nearby
hypothalamus. (B) Peptidergic signal processing within the SCN. (Bi) Glutamate released from RHT terminals activates NMDA receptors, which are
expressed on neurons throughout the SCN [64] (Bii) Signal transduction downstream of NMDAR activation leads to c-FOS induction and peptide
release in a subset of neurons. Intra-SCN signaling is mediated by VIP, GRP and/or little SAAS peptides. (Biii) VIP and GRP transmit signals via VPAC2
and BB2 receptors, respectively. Little SAAS functions independently of VPAC2 or BB2 receptor signaling, and is predicted to function through (Biv) an
unidentified cell surface receptor, and (Bv) downstream signal-processing events.
doi:10.1371/journal.pone.0012612.g007
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little SAAS levels might modulate SCN susceptibility to phase
resetting deserves further evaluation.
Overall, this study has built upon discovery-based peptidomics
to localize and functionally define a context for little SAAS in the
neuropeptidergic circuitry of the SCN. This role for little SAAS is
independent of previously described VIP and GRP signal relay,
positioning little SAAS as a third element in intra-SCN cell-to-cell
communication that mediates resetting of the circadian clock. This
finding further implicates SCN neuropeptidergic heterogeneity in
multi-factorial communication of circadian timekeeping and time-
resetting. While VIP, GRP and little SAAS influence clock phase
shifting in similar ways, different combinations of stimulus type,
clock state and physiological variables may evoke different
contextual roles for these neuropeptides in SCN phase regulation
in vivo. The emerging, unanticipated complexity of SCN
neuropeptide actions emphasizes the need to re-evaluate their
multivariate roles in SCN physiology.
Supporting Information
Figure S1 Specificity of little SAAS antiserum. In order to
evaluate the little SAAS antiserum used in this study, two stringent
tests were performed. The first evaluated SCN immunoreactivity
in transgenic proSAAS-null mice compared with wild types. Little
SAAS staining within the brain tissue of the wild-type mouse (S1A)
is absent in the proSAAS-null mouse tissue (S1B). Similar results
are observed with both antisera #2766 and 2768 against little
SAAS (S1 shows antiserum #2766). The second test evaluated
staining in rat tissue using antisera pre-incubated in 100 mM little
SAAS peptide. When either little SAAS antisera was pre-absorbed,
no little SAAS staining is observed in rat brain (data not shown).
These data validate the specificity of these antisera for little SAAS.
Scale bar=1 mm.
Found at: doi:10.1371/journal.pone.0012612.s001 (1.36 MB TIF)
Figure S2 Enlarged confocal image of VIP/GRP/little SAAS
immunostained rat rostral SCN. Enlargement of Figure 2D reveals
expression of respective peptides in this quadrant of the rat SCN:
VIP (white), GRP (green), little SAAS (red), VIP/little SAAS (pink),
and GRP/little SAAS (yellow). 3V, third ventricle; OX, optic
chiasm. Single optical section, z=0.11 mm. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0012612.s002 (9.47 MB TIF)
Figure S3 Enlarged confocal image of VIP/GRP/little SAAS
immunostained rat rostro-medial SCN. Enlargement of Figure 2I
reveals expression of respective peptides in this quadrant of the rat
SCN: VIP (white), GRP (green), little SAAS (red), VIP/little SAAS
(pink),and GRP/little SAAS (yellow). 3V, third ventricle; OX, optic
chiasm. Single optical section, z=0.11 mm. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0012612.s003 (9.99 MB TIF)
Figure S4 Enlarged confocal image of VIP/GRP/little SAAS
immunostained rat medio-caudal SCN. Enlargement of Figure 2N
reveals expression of respective peptides in this quadrant of the rat
SCN: VIP (white), GRP (green), little SAAS (red), VIP/little SAAS
(pink),and GRP/little SAAS (yellow). 3V, third ventricle; OX, optic
chiasm. Single optical section, z=0.11 mm. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0012612.s004 (9.39 MB TIF)
Figure S5 Enlarged confocal image of VIP/GRP/little SAAS
immunostained rat caudal SCN. Enlargement of Figure 2S reveals
expression of respective peptides in this quadrant of the rat SCN:
VIP (white), GRP (green), little SAAS (red), VIP/little SAAS (pink),
and GRP/little SAAS (yellow). 3V, third ventricle; OX, optic
chiasm. Single optical section, z=0.11 mm. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0012612.s005 (9.80 MB TIF)
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